Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GH3Q
|
|||
| Former ID |
DCL000852
|
|||
| Drug Name |
ITF2357
|
|||
| Synonyms |
Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Duchenne dystrophy [ICD-11: 8C70; ICD-10: G71.0] | Phase 3 | [1] | |
| Essential thrombocythemia [ICD-11: 3B63.1Z] | Phase 2 | [2], [3] | ||
| Myelofibrosis [ICD-11: 2A20.2; ICD-10: D47.4] | Phase 2 | [2], [3] | ||
| Polycythemia vera [ICD-11: 2A20.4; ICD-10: D45] | Phase 2 | [2], [3] | ||
| Company |
Italfarmaco
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H27N3O4
|
|||
| Canonical SMILES |
CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO
|
|||
| InChI |
1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)
|
|||
| InChIKey |
YALNUENQHAQXEA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 497833-27-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:94187
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7490). | |||
| REF 3 | Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. | |||
| REF 4 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.